Table 2 MRI and US findings at baseline and 2 and 12 weeks after starting tocilizumab therapy
Wilcoxon test P value | |||||
|---|---|---|---|---|---|
Week 0 | Week 2 | Week 12 | Week 0 vs week 2 | Week 0 vs week 12 | |
MRI (all four joints) | |||||
Bursitis | 8 (6–9) | 7 (5–8) | 6 (4–7) | 0.109 | 0.005* |
Effusion/synovitis | 7 (5–9) | 7 (6–9) | 7 (5.5–7) | 0.719 | 0.231 |
MRI (both shoulders) | |||||
Bursitis | 4 (2–4) | 4 (3–4) | 3.5 (2–4) | 1.000 | 0.406 |
Effusion/synovitis | 4 (3–5) | 4 (3–5) | 3.5 (3–4) | 0.625 | 0.176 |
MRI (both hips) | |||||
Bursitis | 4 (3–6) | 3 (2–4) | 2 (1.5–3) | 0.031* | < 0.001* |
Effusion/synovitis | 4 (2–4) | 4 (3–4) | 3 (2–4) | 1.000 | 0.117 |
US (all four joints) | |||||
Bursitis | 2 (1–3) | 3 (1–3) | 0.5 (0–2) | 0.575 | 0.029* |
Effusion/synovitis | 3 (2–5) | 3.5 (2–5) | 2 (1–3) | 1.000 | 0.001* |
US (both shoulders) | |||||
Bursitis | 2 (1–3) | 2 (0–3) | 0.5 (0–1) | 0.542 | 0.018* |
Effusion/synovitis | 2 (1–3) | 2.5 (1–4) | 1 (1–2) | 0.781 | 0.059 |
US (both hips) | |||||
Bursitis | 0 (0–1) | 0 (0–0) | 0 (0–0) | 1.000 | 0.625 |
Effusion/synovitis | 2 (0–3) | 1 (0–2) | 0 (0–2) | 0.560 | 0.002* |